Dr. Linehan on Gene Mutations in Papillary Kidney Cancer

W. Marston Linehan, MD
Published: Thursday, Mar 09, 2017



W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.

Hereditary papillary renal carcinoma (HPRC) is a hereditary kidney cancer that is studied to help better understand non-hereditary kidney cancer. The patients with HRPC who have a germline MET-gene mutation are highly likely to develop bilateral, multifocal, type 1 papillary kidney cancer.

The MET-gene is mutated in a significant number of these patients, explains Linehan. The gene is altered in over 80% of tumors from patients with type 1 papillary kidney cancer.
 
SELECTED
LANGUAGE


W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.

Hereditary papillary renal carcinoma (HPRC) is a hereditary kidney cancer that is studied to help better understand non-hereditary kidney cancer. The patients with HRPC who have a germline MET-gene mutation are highly likely to develop bilateral, multifocal, type 1 papillary kidney cancer.

The MET-gene is mutated in a significant number of these patients, explains Linehan. The gene is altered in over 80% of tumors from patients with type 1 papillary kidney cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x